US drug developer XOMA Corp (Nasdaq: XOMA) says that its development partner, French independent drugmaker Laboratoires Servier, has launched its own independent proof-of-concept (POC) clinical program to evaluate the safety and efficacy of gevokizumab, a potent modulator of interleukin-1 beta (IL-1 beta).
XOMA launched a similar POC clinical program in November 2011, which included studies in three separate indications: moderate to severe inflammatory acne vulgaris, erosive inflammatory osteoarthritis of the hand, and non-anterior scleritis. Servier has selected several indications across multiple therapeutic areas.
Servier sees wider indications for the compound
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze